Vaccine Delivery Phases

Age 50+ clinically vulnerable individuals including:

1. People with severe respiratory conditions, including cystic fibrosis, severe asthma and severe chronic obstructive pulmonary disease (COPD)
2. Diabetics
3. People with rare diseases that significantly increase the risk of infections (such as homozygous sickle cell disease)
4. People who had their spleen removed
5. People with very significant developmental disabilities that increase risk (such as Down syndrome)
6. People on dialysis or with chronic kidney disease (stage 5)
7. People with significant neuromuscular conditions requiring respiratory support

Note vulnerable individuals age 12-49 are not currently eligible for second booster doses.

Age 50+ moderately to severely immune compromised individuals that includes:

Stem cell and organ transplant recipients; recipients in active treatment (chemotherapy, targeted therapies, immunotherapy) for malignant, hematologic disorders; recipients of an anti-CD20 agent (e.g. rituximab, ocrelizumab, ofatumumab).

Individuals with primary or acquired immunodeficiency states:

• Including but not limited to poorly controlled HIV/AIDS (i.e. a current CD4 count of <200 cells/µl for adults or children)
• Primary or acquired cellular and combined immune deficiencies

Individuals on immunosuppressive or immunomodulating therapy at the time of vaccination including:

• Those who were receiving or had received in the previous three months targeted therapy and/or immune modulating therapy for autoimmune disease
• Those who were receiving or had received in the previous six months immunosuppressive chemotherapy or radiotherapy for any indication

Individuals with chronic immune-mediated inflammatory disease who were receiving or had received immunosuppressive therapy prior to vaccination including: methotrexate, azathioprine

Individuals who had received high-dose steroids (equivalent to ≥40mg prednisolone per day for more than a week) for any reason in the month before vaccination.

Note moderately to severely immune compromised individuals age 12-49 are not currently eligible for second booster doses.